{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:29:26Z","timestamp":1790630966152,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Ipsen and Novartis"},{"name":"Ipsen, Boulogne Billancourt, France"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background &amp; Aim<\/jats:title><jats:p>Several trials have demonstrated that somatostatin analogues decrease liver volume in mixed populations of patients with autosomal dominant polycystic kidney disease (<jats:styled-content style=\"fixed-case\">ADPKD<\/jats:styled-content>) and isolated polycystic liver disease. Chronic renal dysfunction in <jats:styled-content style=\"fixed-case\">ADPKD<\/jats:styled-content> may affect treatment efficacy of lanreotide and possibly enhances risk for adverse events. The aim of this open\u2010label clinical trial (<jats:styled-content style=\"fixed-case\">RESOLVE<\/jats:styled-content> trial) was to assess the efficacy of 6\u2010month lanreotide treatment, 120\u00a0mg, subcutaneously every 4\u00a0weeks in <jats:styled-content style=\"fixed-case\">ADPKD<\/jats:styled-content> patients with symptomatic polycystic liver disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Primary outcome was change in liver volume after 6\u00a0months; secondary outcomes were changes in kidney volume, estimated glomerular filtration rate (<jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>), symptom relief and health\u2010related quality of life (Euro\u2010Qol5D). We excluded patients with an <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content> &lt;30\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>. We used the Wilcoxon signed\u2010rank test or paired two\u2010sided <jats:italic>t<\/jats:italic>\u2010test to analyze within\u2010group differences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 43 ADPKD patients with polycystic liver disease (84% female, median age 50\u00a0years, mean <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content> 63\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>). Median liver volume decreased from 4859\u00a0ml to 4595\u00a0ml (\u22123.1%; <jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.001), and median kidney volume decreased from 1023\u00a0ml to 1012\u00a0ml (\u22121.7%; <jats:italic>P\u00a0<\/jats:italic>=\u00a00.006). <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content> declined 3.5% after the first injection, remained stable up to study end, to decline again after lanreotide withdrawal. Lanreotide significantly relieved post\u2010prandial fullness, shortness of breath and abdominal distension. Three participants had a suspected episode of hepatic or renal cyst infection during this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Lanreotide reduced polycystic liver and kidney volumes and decreases symptoms in ADPKD patients. Moreover, <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content> decreased acutely after starting lanreotide, stabilized thereafter and declined again after withdrawal. Trial registration number: Clinical trials.gov NCT01354405 (Registration: 13 May 2011).<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.12726","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T13:37:42Z","timestamp":1415108262000},"page":"1607-1614","source":"Crossref","is-referenced-by-count":46,"title":["Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial"],"prefix":"10.1111","volume":"35","author":[{"given":"Tom J.G.","family":"Gevers","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology Radboudumc Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen C.","family":"Hol","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Radboudumc Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Monshouwer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Radboudumc Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena M.","family":"Dekker","sequence":"additional","affiliation":[{"name":"Department of Radiology Radbouumc Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.M.","family":"Wetzels","sequence":"additional","affiliation":[{"name":"Department of Nephrology Radboudumc Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P.H.","family":"Drenth","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Radboudumc Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00080605"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)65165-9"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840110619"},{"key":"e_1_2_9_5_1","first-page":"367","article-title":"Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum","volume":"69","author":"Gulick JJ","year":"2011","journal-title":"Neth J Med"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12430"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-69"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24036"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e328343433f"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04783.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.155721"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05380709"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009121291"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00395.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.07.052"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61407-5"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.04.055"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-13-17"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199703000-00008"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008050507"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9120-6"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054341"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91446-B"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00320.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.292.6537.1701"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.10.011"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04923.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03346419"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01870309"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs152"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03495-3"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12726","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12726","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T12:22:16Z","timestamp":1696162936000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.12726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/liv.12726"],"URL":"https:\/\/doi.org\/10.1111\/liv.12726","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}